# A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke

> **NCT01883011** · PHASE4 · TERMINATED · sponsor: **UCB S.A. - Pharma Sector** · enrollment: 571 (actual)

## Conditions studied

- Acute Ischaemic Middle Cerebral Artery Stroke

## Interventions

- **DRUG:** Piracetam
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01883011
- **Lead sponsor:** UCB S.A. - Pharma Sector
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1998-08
- **Primary completion:** 2001-07
- **Final completion:** 2001-07
- **Target enrollment:** 571 (ACTUAL)
- **Why stopped:** This study was terminated after a pre-specified interim analysis. Please see Detailed Study Description for further information.
- **Last updated:** 2013-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883011, "A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01883011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*